Technical analyst Gaurang Shah of Geojit BNP Paribas has maintained 'buy' rating on Aurobindo Pharma Limited stock for 15-20% returns.

According to analyst, the interested investors can buy the stock on dips to around Rs 165.

Today, the stock of the company opened at Rs 171.90 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 275 and a low of Rs 157.25 on BSE.

Current EPS & P/E ratio stood at 19.31 and 9.02 respectively.

For the third quarter, which finished on December 31, 2010, Aurobindo Pharma's consolidated net profit grew by 9.81% to Rs 188.63 crore as against a net profit of Rs 171.77 crore during the same period of 2009.

Company's net sales surged to Rs 1,192.20 crore for the three month period ended December 2010 from Rs 915.24 crore during the same period of 2009.

Mr. Ramprasad Reddy, Chairman, Aurobindo Pharma stated, "We continue to see a strong momentum in our formulations business with the scaling up of operations of the large formulations units in Jedcherla SEZ near Hyderabad, India and New Jersey, USA."

The Hyderabad-based company registered 15 ANDAs in the third quarter, which takes the cumulative filings to 200.

The UK Medicines and Healthcare products Regulatory Agency allotted the company a marketing approval for the Gabapentin tabs in different potencies comprising 100mg, 300mg and 400mg.